Source:http://linkedlifedata.com/resource/pubmed/id/11807007
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2002-1-24
|
pubmed:abstractText |
Acute promyelocytic leukemia (APL) is characterized by the specific chromosome translocation t(15;17) with promyelocytic leukemia-retinoic acid receptor-alpha (PML-RARA) fusion gene and the ability to undergo terminal differentiation as an effect of all-trans retinoic acid (ATRA). Recently, arsenic trioxide (As(2)O(3)) has been identified as an alternative therapy in patients with both ATRA-sensitive and ATRA-resistant APL. At the cellular level, As(2)O(3) triggers apoptosis and a partial differentiation of APL cells in a dose-dependent manner; both effects are observed in vivo among patients with APL and APL animal models. To further explore the mechanism of As(2)O(3)-induced differentiation, the combined effects of arsenic and a number of other differentiation inducers on APL cell lines (NB4 and NB4-R1) and some fresh APL cells were examined. The data show that a strong synergy exists between a low concentration of As(2)O(3) (0.25 microM) and the cyclic adenosine monophosphate (cAMP) analogue, 8-CPT-cAMP, in fully inducing differentiation of NB4, NB4-R1, and fresh APL cells. Furthermore, cAMP facilitated the degradation of As(2)O(3)-mediated fusion protein PML-RARalpha, a process considered to play a key role in overcoming the differentiation arrest of APL cells. On the other hand, cAMP could significantly inhibit cell growth by modulating several major players in G(1)/S transition regulation. Interestingly, H89, an antagonist of protein kinase A, could block the differentiation-inducing effect of As(2)O(3) potentiated by cAMP. These results thus support the existence of a novel signaling cross-talk for APL maturation, which may deepen understanding of As(2)O(3)-induced differentiation in vivo, and thus furnish insights for new therapeutic strategies.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/8-((4-chlorophenyl)thio)cyclic-3',5'...,
http://linkedlifedata.com/resource/pubmed/chemical/Arsenicals,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclic AMP,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Oncogene Proteins, Fusion,
http://linkedlifedata.com/resource/pubmed/chemical/Oxides,
http://linkedlifedata.com/resource/pubmed/chemical/Thionucleotides,
http://linkedlifedata.com/resource/pubmed/chemical/arsenic trioxide,
http://linkedlifedata.com/resource/pubmed/chemical/promyelocytic leukemia-retinoic...
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0006-4971
|
pubmed:author |
pubmed-author:ChenSai-JuanSJ,
pubmed-author:DoiY KYK,
pubmed-author:FealCC,
pubmed-author:FlexorMariaM,
pubmed-author:JiaPei-MingPM,
pubmed-author:LanotteMichelM,
pubmed-author:ShenYu-LeiYL,
pubmed-author:TongJian-HuaJH,
pubmed-author:WaxmanSamuelS,
pubmed-author:YuYunY,
pubmed-author:ZhangJi-WangJW,
pubmed-author:ZhuHai-QingHQ,
pubmed-author:ZhuQiQ
|
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
99
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1014-22
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:11807007-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11807007-Arsenicals,
pubmed-meshheading:11807007-Cell Differentiation,
pubmed-meshheading:11807007-Cell Division,
pubmed-meshheading:11807007-Cyclic AMP,
pubmed-meshheading:11807007-Drug Synergism,
pubmed-meshheading:11807007-Humans,
pubmed-meshheading:11807007-Leukemia, Promyelocytic, Acute,
pubmed-meshheading:11807007-Neoplasm Proteins,
pubmed-meshheading:11807007-Oncogene Proteins, Fusion,
pubmed-meshheading:11807007-Oxides,
pubmed-meshheading:11807007-Receptor Cross-Talk,
pubmed-meshheading:11807007-Signal Transduction,
pubmed-meshheading:11807007-Thionucleotides,
pubmed-meshheading:11807007-Tumor Cells, Cultured
|
pubmed:year |
2002
|
pubmed:articleTitle |
Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk.
|
pubmed:affiliation |
Shanghai Institute of Hematology and Key Laboratory for Human Genome Research, Rui Jin Hospital, Shanghai Second Medical University, 197 Rui Jin Road II, Shanghai 200025, P.R. China.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|